Hypoxia stimulates 18F-Fluorodeoxyglucose uptake in breast cancer cells via Hypoxia inducible Factor-1 and AMP-activated protein kinase

Nuclear Medicine and Biology

Volumn 40, Issue 6, 2013, Pages 858-864

  Smith, Tim A D ^a   Zanda, Matteo ^b   Fleming, Ian N ^c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c Aberdeen Biomedical Imaging Centre   (United Kingdom)

Author keywords

AMP activated protein kinase; Fluorodeoxyglucose; Hypoxia; Hypoxia inducible factor 1; Oncology, Positron Emission Tomography

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE; ADENOSINE PHOSPHATE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYPOXIA INDUCIBLE FACTOR 1; GLUCOSE; DITHIOTHREITOL; FLUORODEOXYGLUCOSE; HEXOKINASE 2; PHOSPHATE BUFFERED SALINE;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CULTURE; ENZYME ACTIVATION; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; HYPOXIA; MOLECULAR MECHANICS; OXYGENATION; UPREGULATION; WESTERN BLOTTING; BREAST TUMOR; CELL HYPOXIA; DRUG EFFECTS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; TRANSPORT AT THE CELLULAR LEVEL; (18)F-FLUORODEOXYGLUCOSE; (18)F-FLUOROMISONIDAZOLE; 6-PHOSPHOFRUCTO-2-KINASE; [(3)H]-O-METHYLGLUCOSE; AMP-ACTIVATED PROTEIN KINASE; AMPK; CELL STRAIN MCF 7; DRUG EFFECT; FDG; FMISO; HIF1; HK2; MDA231; MDAMB231; OMG; ONCOLOGY, POSITRON EMISSION TOMOGRAPHY; PBS; PET; PFK2; POSITRON EMISSION TOMOGRAPHY;

AMP-ACTIVATED PROTEIN KINASES; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CELL HYPOXIA; DOXORUBICIN; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MCF-7 CELLS;

(18)F-FLUORODEOXYGLUCOSE; (18)F-FLUOROMISONIDAZOLE; 6-PHOSPHOFRUCTO-2-KINASE; [(3)H]-O-METHYLGLUCOSE; AMP-ACTIVATED PROTEIN KINASE; AMPK; DITHIOTHREITOL; DTT; FDG; FLUORODEOXYGLUCOSE; FMISO; HEXOKINASE 2; HIF1; HK2; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR 1; MDA231; MDAMB231; OMG; ONCOLOGY, POSITRON EMISSION TOMOGRAPHY; PBS; PET; PFK2; PHOSPHATE BUFFERED SALINE; POSITRON EMISSION TOMOGRAPHY;

EID: 84881022665     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.05.006     Document Type: Article

References (35)

1. Lundgren K., Holm C., Landberg G. Hypoxia and breast cancer: prognostic and therapeutic implications. Cellular and molecular life sciences: CMLS 2007, 64(24):3233-3247.
2. Kalliomäki T.M., McCallum G., Wells P.G., Hill R.P. Progression and metastasis in a transgenic mouse breast cancer model: effects of exposure to in vivo hypoxia. Cancer Lett 2009, 282(1):98-108.
3. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996, 56(5):941-943.
4. Mees G., Dierckx R., Vangestel C., Van De Wiele C. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging 2009, 36(10):1674-1686.
5. Le Q.-, Courter D. Clinical biomarkers for hypoxia targeting. Cancer Metastasis Rev 2008, 27(3):351-362.
6. McSheehy P.M.J., Leach M.O., Judson I.R., Griffiths J.R. Metabolites of 2'-fluoro-2'-deoxy-D-glucose detected by 19F magnetic resonance spectroscopy in vivo predict response of murine RIF-1 tumors to 5- fluorouracil. Cancer Res 2000, 60(8):2122-2127.
7. Airley R.E., Mobasheri A. Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 2007, 53(4):233-256.
8. Warburg O. On respiratory impairment in cancer cells. Science 1956, 124(3215):269-270.
9. Burgman P., O'Donoghue J.A., Humm J.L., Ling C.C. Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med 2001, 42(1):170-175.
10. Oswald J., Treite F., Haase C., Kampfrath T., Mäding P., Schwenzer B., et al. Experimental hypoxia is a potent stimulus for radiotracer uptake in vitro: comparison of different tumor cells and primary endothelial cells. Cancer Lett 2007, 254(1):102-110.
11. Clavo A.C., Brown R.S., Wahl R.L. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med 1995, 36(9):1625-1632.
12. Minn H., Clavo A.C., Wahl R.L. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol 1996, 23(8):941-946.
13. Hara T., Bansal A., DeGrado T.R. Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells. Nucl Med Biol 2006, 33(8):977-984.
14. Stubbs M., Griffiths J.R. The altered metabolism of tumors: HIF-1 and its role in the Warburg effect. Adv Enzyme Regul 2010, 50(1):44-55.
15. Towler M.C., Hardie D.G. AMP-activated protein kinase in metabolic control and insulin signaling. Circ Res 2007, 100(3):328-341.
16. Barnes K., Ingram J.C., Porras O.H., Barros L.F., Hudson E.R., Fryer L.G.D., et al. Activation of GLUT1 by metabolic and osmotic stress: potential involvement of AMP-activated protein kinase (AMPK). J Cell Sci 2002, 115(11):2433-2442.
17. Jung S.-, Yang W.K., Kim J., Kim H.S., Kim E.J., Yun H., et al. Reactive oxygen species stabilize hypoxia-inducible factor-1 alpha protein and stimulate transcriptional activity via AMP-activated protein kinase in DU145 human prostate cancer cells. Carcinogenesis 2008, 29(4):713-721.
18. Dearling J.L.J., Flynn A.A., Sutcliffe-Goulden J., Petrie I.A., Boden R., Green A.J., et al. Analysis of the regional uptake of radiolabeled deoxyglucose analogs in human tumor xenografts. J Nucl Med 2004, 45(1):101-107.
19. Wyss M.T., Honer M., Schubiger P.A., Ametamey S.M. NanoPET imaging of [ 18F]fluoromisonidazole uptake in experimental mouse tumours. Eur J Nucl Med Mol Imaging 2006, 33(3):311-318.
20. Zanzonico P., Campa J., Polycarpe-Holman D., Forster G., Finn R., Larson S., et al. Animal-specific positioning molds for registration of repeat imaging studies: comparative microPET imaging of F18-labeled fluoro-deoxyglucose and fluoro-misonidazole in rodent tumors. Nucl Med Biol 2006, 33(1):65-70.
21. Rajendran J.G., Mankoff D.A., O'Sullivan F., Peterson L.M., Schwartz D.L., Conrad E.U., et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004, 10(7):2245-2252.
22. Zimny M., Gagel B., DiMartino E., Hamacher K., Coenen H.H., Westhofen M., et al. FDG - a marker of tumour hypoxia? A comparison with [18F] fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 2006, 33(12):1426-1431.
23. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98(19):10869-10874.
24. Sun Y., Luo D., Liao D. CyclinD1 protein plays different roles in modulating chemoresponses in MCF7 and MDA-MB231 cells. Journal of Carcinogenesis 2012, 11.
25. Smith T.A.D., Sharma R.I., Thompson A.M., Paulin F.E.M. Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro. J Nucl Med 2006, 47(9):1525-1530.
26. Sharma R.I., Smith T.A.D. Colorectal tumor cells treated with 5-FU, oxaliplatin, irinotecan, and cetuximab exhibit changes in 18F-FDG incorporation corresponding to hexokinase activity and glucose transport. J Nucl Med 2008, 49(8):1386-1394.
27. Sargeant R.J., Paquet M.R. Effect of insulin on the rates of synthesis and degradation of GLUT1 and GLUT4 glucose transporters in 3T3-L1 adipocytes. Biochem J 1993, 290(3):913-919.
28. Lau C.K., Yang Z.F., Lam C.T., Tam K.H., Poon R.T.P., Fan S.T. Suppression of hypoxia inducible factor-1α (HIF-1α) by YC-1 is dependent on murine double minute 2 (Mdm2). Biochem Biophys Res Commun 2006, 348(4):1443-1448.
29. Avril N., Sassen S., Roylance R. Response to therapy in breast cancer. J Nucl Med 2009, 50(Suppl 1):55S-63S.
30. Li Y., Zhao X., Tang H., Zhong Z., Zhang L., Xu R., et al. Effects of YC-1 on hypoxia-inducible factor 1 alpha in hypoxic human bladder transitional carcinoma cell line T24 cells. Urol Int 2012, 88(1):95-101.
31. Seo M., Kim J.-, Neau D., Sehgal I., Y- Lee Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect. PLoS One 2011, 6(9).
32. Atsumi T., Chesney J., Metz C., Leng L., Donnelly S., Makita Z., et al. High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res 2002, 62(20):5881-5887.
33. Fleming I.N., Regel S.J., Pike L.C., Marsden P.K., Gilbert F.J. Positron emission tomography oncology research in the UK: a comparison with USA and Europe. Nucl Med Commun 2012, 33(4):341-348.
34. Wang K., Yorke E., Nehmeh S.A., Humm J.L., Ling C.C. Modeling acute and chronic hypoxia using serial images of 18F-FMISO PET. Med Phys 2009, 36(10):4400-4408.
35. Dierckx R.A., Van De Wiele C. FDG uptake, a surrogate of tumour hypoxia?. Eur J Nucl Med Mol Imaging 2008, 35(8):1544-1549.